Drug-induced extrapyramidal disorders.
D000978:Antiparkinson Agents / Q000009:adverse effects; D001058:Apomorphine / Q000009:adverse effects; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001590:Benztropine / Q000009:adverse effects; D004295:Dihydroxyphenylalanine / Q000009:adverse effects; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D064420:Drug-Related Side Effects and Adverse Reactions; D005116:Extrapyramidal Tracts / Q000187:drug effects*; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D008781:Methyltyrosines / Q000009:adverse effects; D009069:Movement Disorders / Q000139:chemically induced*; D010640:Phenothiazines / Q000009:adverse effects; D010648:Phenylacetates / Q000378:metabolism; D011339:Probenecid / Q000009:adverse effects; D012110:Reserpine / Q000009:adverse effects; D009435:Synaptic Transmission / Q000187:drug effects*; D013747:Tetrabenazine / Q000009:adverse effects; D014149:Tranquilizing Agents / Q000009:adverse effects; D014282:Trihexyphenidyl / Q000009:adverse effects
D000978:Antiparkinson Agents; D008781:Methyltyrosines; D010640:Phenothiazines; D010648:Phenylacetates; D014149:Tranquilizing Agents; D001590:Benztropine; D004295:Dihydroxyphenylalanine; D014282:Trihexyphenidyl; D012110:Reserpine; D006220:Haloperidol; D001058:Apomorphine; D011339:Probenecid; D004298:Dopamine; D013747:Tetrabenazine